MemoHoney vs. Ginkgo Biloba: Two Circulation Approaches to Brain Support
Ginkgo biloba (EGb 761 extract, 120–240 mg/day) supports microcirculation and has the largest cognitive trial base of any botanical — mostly null in healthy adults, modestly positive in mild impairment — with a documented bleeding interaction. MemoHoney supports circulation via nitric oxide precursors at modest doses with no bleeding risk but no finished-product trials. Ginkgo has more evidence; MemoHoney has fewer interactions.
- Ginkgo: 120–240 mg EGb 761
- Bleeding risk with anticoagulants
- MemoHoney: no platelet effect
- Both: circulation mechanism
How Ginkgo works
Standardised Ginkgo extract contains flavonoid glycosides and terpene lactones. The flavonoids are antioxidants and mild vasodilators; the terpenes, especially ginkgolide B, inhibit platelet-activating factor, which reduces platelet aggregation and improves blood rheology in small vessels. Together they improve microcirculation — a mechanism adjacent to MemoHoney's, arrived at from a different direction.
What the Ginkgo evidence says
The largest trial, GEM, followed 3,000 older adults for six years at 240 mg/day and found no reduction in dementia incidence or cognitive decline. Smaller trials in people with existing mild cognitive impairment show modest improvements in some cognitive scales. In healthy adults, results are inconsistent. The honest summary: Ginkgo is well tolerated, does something to microcirculation, and has not demonstrated meaningful cognitive benefit in healthy people despite extensive testing.
The interaction that matters
Because ginkgolides inhibit platelet aggregation, Ginkgo increases bleeding risk with warfarin, aspirin, clopidogrel and NSAIDs, and is routinely stopped before surgery. Case reports of spontaneous bleeding exist. This is the single biggest reason a pharmacist would prefer a nitric oxide formula over Ginkgo for a patient on anticoagulants — with the caveat that nitric oxide precursors carry their own blood-pressure interactions.
Where MemoHoney stands
MemoHoney has no platelet effect and no herbal variability — amino acids and a vitamin are the same batch to batch in a way botanical extracts are not. It has the disclosed-label advantage. It lacks any finished-product trial and its doses are modest. If your circulation concern is microvascular and you are not on blood thinners, Ginkgo has more data. If you are on blood thinners, or you prefer a simpler and fully specified formula, MemoHoney is the conservative pick — with its blood-pressure caveat.
What this means for MemoHoney
Ginkgo and MemoHoney are the two circulation-first options in the brain supplement aisle. Ginkgo wins on evidence volume; MemoHoney wins on label clarity and freedom from bleeding interactions. Neither has convincing cognitive data in healthy adults.
| Ingredient | Per capsule | Research / RDA range |
|---|---|---|
| Niacin (Vitamin B3) | 7.5 mg NE | 14–16 mg NE (RDA) |
| Calcium | 18 mg | 1,000–1,200 mg (RDA) |
| L-Arginine (base) | 200 mg | 3,000–6,000 mg |
| L-Arginine AKG 2:1 | 200 mg | 3,000–6,000 mg |
| L-Citrulline HCl | 100 mg | 3,000–8,000 mg |
| L-Citrulline Malate | 100 mg | 3,000–8,000 mg |
| Beta-Alanine | 40 mg | 2,000–6,000 mg |
Every MemoHoney amount is printed on the label — no proprietary blend. Full analysis on the ingredients page; mechanism on how it works.
Key takeaways
- Ginkgo: more trials, mostly null in healthy adults, bleeding interaction.
- MemoHoney: cleaner label, no platelet effect, no product trials.
- Choice depends on your medications more than on efficacy data.
FAQ
Physically yes, but you stack two circulation effects. Anyone on blood pressure or blood-thinning medication should ask a doctor first.
In healthy adults, no. Modest benefits appear in some trials of mild cognitive impairment.
For people on anticoagulants, MemoHoney. For people on antihypertensives or nitrates, arguably Ginkgo. Both are safe for healthy adults not on medication.